glp-1 and gip/glp-1 receptor agonists Science Behind GLP 1 GIP Glucagon for Obesity Research | News & Announcements Dual GIP/GLP-1 receptor agonists: New

Results Seven trials (6609 participants) were included

95% CI 0.750.98, p=0.03), Dulaglutide (RR 0.82, 95% CI 0.700.96, p=0.02), Albiglutide (RR 0.93,95% CI 0.791.10, p=0.40), Exenatide (RR 0.93, 95% CI 0.741.18, p=0.55), Lixisenatide (RR 0.83, 95% CI 0.621.12, p=0.22), and Efpeglenatide (RR 0.76, 95% CI 0.461.24, p=0.27)

and increased insulin early AUC and C-peptide total and early AUCs

Premier Physicians Weight Loss & Wellness provides physician-supervised weight loss medication management in Las Vegas and Reno

Read highlights from the released 2025 Standards of Care, including recommendations for CGM use in type 2 diabetes for the first time, the use of GLP-1 drugs for kidney and heart benefits and a warning of DKA risk in recreational marijuana use.